Literature DB >> 20149605

Biliary intervention aggravates cholestatic liver injury, and induces hepatic inflammation, proliferation and fibrogenesis in BDL mice.

Yang-An Wen1, Ding Liu, Qian-Yun Zhou, Shi-Feng Huang, Peng Luo, Yu Xiang, Shan Sun, Dan Luo, Yu-Fang Dong, Li-Ping Zhang.   

Abstract

Obstructive cholestasis occurs in various clinical situations, whose pathological process is complex and not well known. The present study was initiated to display the complex and multifaceted pathological process caused by obstructive cholestasis in bile duct-ligated mice. Adult mice were bile-duct-ligated or sham-operated, and serum and liver tissues were collected at the indicated time points. Automatic biochemical analyzer was used to monitor serum biochemical index; TUNEL, HE staining, immunohistochemistry and Real-time PCR were employed to evaluate liver apoptosis, necrosis, inflammation, as well as proliferation and fibrosis. Our results demonstrated that obstructive cholestasis led to elevated serum biochemical indicators, with ALT peaking at day 3, indicative of acute hepatic dysfunction. Meanwhile, the number of TUNEL-positive cells increased significantly, and by 2 weeks, mild to moderate necrosis became apparent in BDL mouse livers, which consequently aggravated hepatic inflammatory responses as was demonstrated by increased expression of KC-1, MIP-2, ICAM-1 and MPO in BDL mouse livers. Moreover, proliferative hepatocytes around periportal areas, manifested by enhanced cell mitosis and elevated expression of proliferative markers such as PCNA and Ki67, increased significantly after BDL, while increased CK-19-positive cells in bile ducts indicated bile duct hyperplasia. By 2 weeks, numerous α-SMA-positive cells and Sirius-stained collagen were observed, indicative of hepatic stellate cells (HSC) activation and fibrogenesis. In conclusion, biliary intervention led to a multifaceted hepatic pathological process characterized by aggravated liver injury and inflammatory reaction with enhanced cellular proliferation and fibrogenesis. Crown
Copyright © 2010. Published by Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20149605     DOI: 10.1016/j.etp.2010.01.006

Source DB:  PubMed          Journal:  Exp Toxicol Pathol        ISSN: 0940-2993


  7 in total

1.  Protective effects of thymoquinone against cholestatic oxidative stress and hepatic damage after biliary obstruction in rats.

Authors:  Serhat Oguz; Mehmet Kanter; Mustafa Erboga; Cengiz Erenoglu
Journal:  J Mol Histol       Date:  2012-01-21       Impact factor: 2.611

2.  Promoting the recovery of injured liver with poly (3-hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate) scaffolds loaded with umbilical cord-derived mesenchymal stem cells.

Authors:  Pengshan Li; Jin Zhang; Jing Liu; Huan Ma; Jie Liu; Puchang Lie; Yuechun Wang; Gexiu Liu; Huilan Zeng; Zhizhong Li; Xing Wei
Journal:  Tissue Eng Part A       Date:  2014-11-14       Impact factor: 3.845

3.  The efficiency of CAPE on retardation of hepatic fibrosis in biliary obstructed rats.

Authors:  Ahmet Tomur; Mehmet Kanter; Ahmet Gurel; Mustafa Erboga
Journal:  J Mol Histol       Date:  2011-08-06       Impact factor: 2.611

4.  S100 calcium binding protein A6 and associated long noncoding ribonucleic acids as biomarkers in the diagnosis and staging of primary biliary cholangitis.

Authors:  Xi-Hua Dong; Di Dai; Zhi-Dong Yang; Xiao-Ou Yu; Hua Li; Hui Kang
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

Review 5.  Roles of hepatic stellate cells in acute liver failure: From the perspective of inflammation and fibrosis.

Authors:  Juan Li; Ying-Ren Zhao; Zhen Tian
Journal:  World J Hepatol       Date:  2019-05-27

Review 6.  Molecular mechanisms of hepatic apoptosis.

Authors:  K Wang
Journal:  Cell Death Dis       Date:  2014-01-16       Impact factor: 8.469

7.  Modulation of HIF-1α and STAT3 signaling contributes to anti-angiogenic effect of YC-1 in mice with liver fibrosis.

Authors:  Tzung-Yan Lee; Yann-Lii Leu; Chorng-Kai Wen
Journal:  Oncotarget       Date:  2017-09-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.